Skip to main content
PMC home page
Transactions of the American Ophthalmological Society logoLink to Transactions of the American Ophthalmological Society
. 2000;98:493–503.

Hyperhomocysteinemia: a new risk factor for central retinal vein occlusion.

A K Vine 1
PMCID: PMC1298239  PMID: 11190038

Abstract

PURPOSE: Previous studies have documented that an elevated plasma homocysteine level is a risk factor for vascular disease. The purpose of this study is to determine whether hyperhomocysteinemia is a risk factor for central retinal vein occlusion. METHODS: This case-controlled study involved reassessment of 74 patients with documented central retinal vein occlusion. Control subjects consisted of individuals referred to the same clinic for assessment of a nonretinal vascular disease. Hyperhomocysteinemia was defined as a total plasma homocysteine level above the 95th percentile in the control group. RESULTS: The mean total plasma homocysteine level was 11.58 mumol/L for cases and 9.49 mumol/L for controls. Of the 74 patients with a central retinal vein occlusion, 21.6% had total plasma homocysteine levels above the 95th percentile in the control group (odds ratio, 6.53; 95% confidence interval, 1.81 to 23.50, P = .003). Hyperhomocysteinemia was present in 55% of cases with bilateral disease, 30% of ischemic cases, and 31% of cases with severe visual loss. CONCLUSION: Hyperhomocysteinemia is a risk factor for central retinal vein occlusion.

Full text

PDF
495

Images in this article

494FIGURE 1
on p.494

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson A., Brattström L., Israelsson B., Isaksson A., Hamfelt A., Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest. 1992 Feb;22(2):79–87. doi: 10.1111/j.1365-2362.1992.tb01940.x. [DOI] [PubMed] [Google Scholar]
  2. Appel L. J. Folic acid fortification of food. JAMA. 1996 Mar 6;275(9):681–683. doi: 10.1001/jama.1996.03530330025013. [DOI] [PubMed] [Google Scholar]
  3. Biousse V., Newman N. J., Sternberg P., Jr Retinal vein occlusion and transient monocular visual loss associated with hyperhomocystinemia. Am J Ophthalmol. 1997 Aug;124(2):257–260. doi: 10.1016/s0002-9394(14)70800-1. [DOI] [PubMed] [Google Scholar]
  4. Bostom A. G., Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997 Jul;52(1):10–20. doi: 10.1038/ki.1997.298. [DOI] [PubMed] [Google Scholar]
  5. Boushey C. J., Beresford S. A., Omenn G. S., Motulsky A. G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995 Oct 4;274(13):1049–1057. doi: 10.1001/jama.1995.03530130055028. [DOI] [PubMed] [Google Scholar]
  6. Brattström L., Tengborn L., Lagerstedt C., Israelsson B., Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis. 1991;21(1):51–57. doi: 10.1159/000216202. [DOI] [PubMed] [Google Scholar]
  7. CARSON N. A., NEILL D. W. Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child. 1962 Oct;37:505–513. doi: 10.1136/adc.37.195.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chasan-Taber L., Selhub J., Rosenberg I. H., Malinow M. R., Terry P., Tishler P. V., Willett W., Hennekens C. H., Stampfer M. J. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr. 1996 Apr;15(2):136–143. doi: 10.1080/07315724.1996.10718578. [DOI] [PubMed] [Google Scholar]
  9. Clarke R., Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk. 1998 Aug;5(4):249–255. [PubMed] [Google Scholar]
  10. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 Apr 25;324(17):1149–1155. doi: 10.1056/NEJM199104253241701. [DOI] [PubMed] [Google Scholar]
  11. Elman M. J., Bhatt A. K., Quinlan P. M., Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology. 1990 Nov;97(11):1543–1548. doi: 10.1016/s0161-6420(90)32379-5. [DOI] [PubMed] [Google Scholar]
  12. Falcon C. R., Cattaneo M., Panzeri D., Martinelli I., Mannucci P. M. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb. 1994 Jul;14(7):1080–1083. doi: 10.1161/01.atv.14.7.1080. [DOI] [PubMed] [Google Scholar]
  13. Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G. J., den Heijer M., Kluijtmans L. A., van den Heuvel L. P. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111–113. doi: 10.1038/ng0595-111. [DOI] [PubMed] [Google Scholar]
  14. Graham I. M., Daly L. E., Refsum H. M., Robinson K., Brattström L. E., Ueland P. M., Palma-Reis R. J., Boers G. H., Sheahan R. G., Israelsson B. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997 Jun 11;277(22):1775–1781. doi: 10.1001/jama.1997.03540460039030. [DOI] [PubMed] [Google Scholar]
  15. Greaves M. Aging and the pathogenesis of retinal vein thrombosis. Br J Ophthalmol. 1997 Oct;81(10):810–811. doi: 10.1136/bjo.81.10.810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Green W. R., Chan C. C., Hutchins G. M., Terry J. M. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc. 1981;79:371–422. [PMC free article] [PubMed] [Google Scholar]
  17. Guba S. C., Fink L. M., Fonseca V. Hyperhomocysteinemia. An emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol. 1996 Dec;106(6):709–722. doi: 10.1093/ajcp/106.6.709. [DOI] [PubMed] [Google Scholar]
  18. Guttormsen A. B., Schneede J., Fiskerstrand T., Ueland P. M., Refsum H. M. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr. 1994 Oct;124(10):1934–1941. doi: 10.1093/jn/124.10.1934. [DOI] [PubMed] [Google Scholar]
  19. Harker L. A., Ross R., Slichter S. J., Scott C. R. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976 Sep;58(3):731–741. doi: 10.1172/JCI108520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Harker L. A., Slichter S. J., Scott C. R., Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med. 1974 Sep 12;291(11):537–543. doi: 10.1056/NEJM197409122911101. [DOI] [PubMed] [Google Scholar]
  21. Hofmann M. A., Kohl B., Zumbach M. S., Borcea V., Bierhaus A., Henkels M., Amiral J., Fiehn W., Ziegler R., Wahl P. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care. 1997 Dec;20(12):1880–1886. doi: 10.2337/diacare.20.12.1880. [DOI] [PubMed] [Google Scholar]
  22. Hughes H., Mathews B., Lenz M. L., Guyton J. R. Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol. Arterioscler Thromb. 1994 Jul;14(7):1177–1185. doi: 10.1161/01.atv.14.7.1177. [DOI] [PubMed] [Google Scholar]
  23. Jacob R. A., Wu M. M., Henning S. M., Swendseid M. E. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J Nutr. 1994 Jul;124(7):1072–1080. doi: 10.1093/jn/124.7.1072. [DOI] [PubMed] [Google Scholar]
  24. Loewenstein A., Goldstein M., Winder A., Lazar M., Eldor A. Retinal vein occlusion associated with methylenetetrahydrofolate reductase mutation. Ophthalmology. 1999 Sep;106(9):1817–1820. doi: 10.1016/S0161-6420(99)90357-3. [DOI] [PubMed] [Google Scholar]
  25. Loewenstein A., Winder A., Goldstein M., Lazar M., Eldor A. Bilateral retinal vein occlusion associated with 5,10-methylenetetrahydrofolate reductase mutation. Am J Ophthalmol. 1997 Dec;124(6):840–841. doi: 10.1016/s0002-9394(14)71703-9. [DOI] [PubMed] [Google Scholar]
  26. MUDD S. H., FINKELSTEIN J. D., IRREVERRE F., LASTER L. HOMOCYSTINURIA: AN ENZYMATIC DEFECT. Science. 1964 Mar 27;143(3613):1443–1445. doi: 10.1126/science.143.3613.1443. [DOI] [PubMed] [Google Scholar]
  27. Ma J., Stampfer M. J., Hennekens C. H., Frosst P., Selhub J., Horsford J., Malinow M. R., Willett W. C., Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996 Nov 15;94(10):2410–2416. doi: 10.1161/01.cir.94.10.2410. [DOI] [PubMed] [Google Scholar]
  28. Malinow M. R., Duell P. B., Hess D. L., Anderson P. H., Kruger W. D., Phillipson B. E., Gluckman R. A., Block P. C., Upson B. M. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998 Apr 9;338(15):1009–1015. doi: 10.1056/NEJM199804093381501. [DOI] [PubMed] [Google Scholar]
  29. Malinow M. R., Kang S. S., Taylor L. M., Wong P. W., Coull B., Inahara T., Mukerjee D., Sexton G., Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989 Jun;79(6):1180–1188. doi: 10.1161/01.cir.79.6.1180. [DOI] [PubMed] [Google Scholar]
  30. Malinow M. R., Nieto F. J., Szklo M., Chambless L. E., Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation. 1993 Apr;87(4):1107–1113. doi: 10.1161/01.cir.87.4.1107. [DOI] [PubMed] [Google Scholar]
  31. McAndrew P. E., Brandt J. T., Pearl D. K., Prior T. W. The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans. Thromb Res. 1996 Jul 15;83(2):195–198. doi: 10.1016/0049-3848(96)00121-1. [DOI] [PubMed] [Google Scholar]
  32. McCully K. S. Homocysteine and vascular disease. Nat Med. 1996 Apr;2(4):386–389. doi: 10.1038/nm0496-386. [DOI] [PubMed] [Google Scholar]
  33. McCully K. S., Ragsdale B. D. Production of arteriosclerosis by homocysteinemia. Am J Pathol. 1970 Oct;61(1):1–11. [PMC free article] [PubMed] [Google Scholar]
  34. McCully K. S. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969 Jul;56(1):111–128. [PMC free article] [PubMed] [Google Scholar]
  35. McCully K. S., Wilson R. B. Homocysteine theory of arteriosclerosis. Atherosclerosis. 1975 Sep-Oct;22(2):215–227. doi: 10.1016/0021-9150(75)90004-0. [DOI] [PubMed] [Google Scholar]
  36. Morgan S. L., Baggott J. E., Lee J. Y., Alarcón G. S. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol. 1998 Mar;25(3):441–446. [PubMed] [Google Scholar]
  37. Morrison H. I., Schaubel D., Desmeules M., Wigle D. T. Serum folate and risk of fatal coronary heart disease. JAMA. 1996 Jun 26;275(24):1893–1896. doi: 10.1001/jama.1996.03530480035037. [DOI] [PubMed] [Google Scholar]
  38. Mudd S. H., Skovby F., Levy H. L., Pettigrew K. D., Wilcken B., Pyeritz R. E., Andria G., Boers G. H., Bromberg I. L., Cerone R. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985 Jan;37(1):1–31. [PMC free article] [PubMed] [Google Scholar]
  39. Nygård O., Nordrehaug J. E., Refsum H., Ueland P. M., Farstad M., Vollset S. E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997 Jul 24;337(4):230–236. doi: 10.1056/NEJM199707243370403. [DOI] [PubMed] [Google Scholar]
  40. Nygård O., Refsum H., Ueland P. M., Vollset S. E. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr. 1998 Feb;67(2):263–270. doi: 10.1093/ajcn/67.2.263. [DOI] [PubMed] [Google Scholar]
  41. Nygård O., Vollset S. E., Refsum H., Stensvold I., Tverdal A., Nordrehaug J. E., Ueland M., Kvåle G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 1995 Nov 15;274(19):1526–1533. doi: 10.1001/jama.1995.03530190040032. [DOI] [PubMed] [Google Scholar]
  42. Oakley G. P., Jr Eat right and take a multivitamin. N Engl J Med. 1998 Apr 9;338(15):1060–1061. doi: 10.1056/NEJM199804093381509. [DOI] [PubMed] [Google Scholar]
  43. Omenn G. S., Beresford S. A., Motulsky A. G. Preventing coronary heart disease: B vitamins and homocysteine. Circulation. 1998 Feb 10;97(5):421–424. doi: 10.1161/01.cir.97.5.421. [DOI] [PubMed] [Google Scholar]
  44. Oshaug A., Bugge K. H., Refsum H. Diet, an independent determinant for plasma total homocysteine. A cross sectional study of Norwegian workers on platforms in the North Sea. Eur J Clin Nutr. 1998 Jan;52(1):7–11. doi: 10.1038/sj.ejcn.1600505. [DOI] [PubMed] [Google Scholar]
  45. Perry I. J., Refsum H., Morris R. W., Ebrahim S. B., Ueland P. M., Shaper A. G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995 Nov 25;346(8987):1395–1398. doi: 10.1016/s0140-6736(95)92407-8. [DOI] [PubMed] [Google Scholar]
  46. Petri M., Roubenoff R., Dallal G. E., Nadeau M. R., Selhub J., Rosenberg I. H. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996 Oct 26;348(9035):1120–1124. doi: 10.1016/S0140-6736(96)03032-2. [DOI] [PubMed] [Google Scholar]
  47. Refsum H., Ueland P. M., Nygård O., Vollset S. E. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31–62. doi: 10.1146/annurev.med.49.1.31. [DOI] [PubMed] [Google Scholar]
  48. Ridker P. M., Hennekens C. H., Selhub J., Miletich J. P., Malinow M. R., Stampfer M. J. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997 Apr 1;95(7):1777–1782. doi: 10.1161/01.cir.95.7.1777. [DOI] [PubMed] [Google Scholar]
  49. Rimm E. B., Willett W. C., Hu F. B., Sampson L., Colditz G. A., Manson J. E., Hennekens C., Stampfer M. J. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998 Feb 4;279(5):359–364. doi: 10.1001/jama.279.5.359. [DOI] [PubMed] [Google Scholar]
  50. Robinson K., Arheart K., Refsum H., Brattström L., Boers G., Ueland P., Rubba P., Palma-Reis R., Meleady R., Daly L. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation. 1998 Feb 10;97(5):437–443. doi: 10.1161/01.cir.97.5.437. [DOI] [PubMed] [Google Scholar]
  51. Rodgers G. M., Conn M. T. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990 Feb 15;75(4):895–901. [PubMed] [Google Scholar]
  52. Selhub J., Jacques P. F., Bostom A. G., D'Agostino R. B., Wilson P. W., Belanger A. J., O'Leary D. H., Wolf P. A., Schaefer E. J., Rosenberg I. H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995 Feb 2;332(5):286–291. doi: 10.1056/NEJM199502023320502. [DOI] [PubMed] [Google Scholar]
  53. Selhub J., Jacques P. F., Wilson P. W., Rush D., Rosenberg I. H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993 Dec 8;270(22):2693–2698. doi: 10.1001/jama.1993.03510220049033. [DOI] [PubMed] [Google Scholar]
  54. Simioni P., Prandoni P., Burlina A., Tormene D., Sardella C., Ferrari V., Benedetti L., Girolami A. Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost. 1996 Dec;76(6):883–886. [PubMed] [Google Scholar]
  55. Stamler J. S., Osborne J. A., Jaraki O., Rabbani L. E., Mullins M., Singel D., Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993 Jan;91(1):308–318. doi: 10.1172/JCI116187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Stampfer M. J., Malinow M. R., Willett W. C., Newcomer L. M., Upson B., Ullmann D., Tishler P. V., Hennekens C. H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992 Aug 19;268(7):877–881. [PubMed] [Google Scholar]
  57. Stampfer M. J., Willett W. C. Homocysteine and marginal vitamin deficiency. The importance of adequate vitamin intake. JAMA. 1993 Dec 8;270(22):2726–2727. [PubMed] [Google Scholar]
  58. Sutton-Tyrrell K., Bostom A., Selhub J., Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation. 1997 Sep 16;96(6):1745–1749. doi: 10.1161/01.cir.96.6.1745. [DOI] [PubMed] [Google Scholar]
  59. Tsai J. C., Perrella M. A., Yoshizumi M., Hsieh C. M., Haber E., Schlegel R., Lee M. E. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6369–6373. doi: 10.1073/pnas.91.14.6369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Ubbink J. B., Vermaak W. J., van der Merwe A., Becker P. J. The effect of blood sample aging and food consumption on plasma total homocysteine levels. Clin Chim Acta. 1992 Apr 30;207(1-2):119–128. doi: 10.1016/0009-8981(92)90155-j. [DOI] [PubMed] [Google Scholar]
  61. Ubbink J. B., van der Merwe A., Delport R., Allen R. H., Stabler S. P., Riezler R., Vermaak W. J. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest. 1996 Jul 1;98(1):177–184. doi: 10.1172/JCI118763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Ueland P. M., Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989 Nov;114(5):473–501. [PubMed] [Google Scholar]
  63. Ueland P. M., Refsum H., Stabler S. P., Malinow M. R., Andersson A., Allen R. H. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993 Sep;39(9):1764–1779. [PubMed] [Google Scholar]
  64. Van den Berg M., Boers G. H., Franken D. G., Blom H. J., Van Kamp G. J., Jakobs C., Rauwerda J. A., Kluft C., Stehouwert C. D. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 1995 Mar;25(3):176–181. doi: 10.1111/j.1365-2362.1995.tb01545.x. [DOI] [PubMed] [Google Scholar]
  65. Verhoef P., Stampfer M. J., Buring J. E., Gaziano J. M., Allen R. H., Stabler S. P., Reynolds R. D., Kok F. J., Hennekens C. H., Willett W. C. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol. 1996 May 1;143(9):845–859. doi: 10.1093/oxfordjournals.aje.a008828. [DOI] [PubMed] [Google Scholar]
  66. Vine A. K., Samama M. M. Screening for resistance to activated protein C and the mutant gene for factor V:Q506 in patients with central retinal vein occlusion. Am J Ophthalmol. 1997 Nov;124(5):673–676. doi: 10.1016/s0002-9394(14)70905-5. [DOI] [PubMed] [Google Scholar]
  67. Wald N. J., Watt H. C., Law M. R., Weir D. G., McPartlin J., Scott J. M. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 1998 Apr 27;158(8):862–867. doi: 10.1001/archinte.158.8.862. [DOI] [PubMed] [Google Scholar]
  68. Welch G. N., Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998 Apr 9;338(15):1042–1050. doi: 10.1056/NEJM199804093381507. [DOI] [PubMed] [Google Scholar]
  69. Wenzler E. M., Rademakers A. J., Boers G. H., Cruysberg J. R., Webers C. A., Deutman A. F. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol. 1993 Feb 15;115(2):162–167. doi: 10.1016/s0002-9394(14)73919-4. [DOI] [PubMed] [Google Scholar]
  70. Wilcken D. E., Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest. 1976 Apr;57(4):1079–1082. doi: 10.1172/JCI108350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. den Heijer M., Blom H. J., Gerrits W. B., Rosendaal F. R., Haak H. L., Wijermans P. W., Bos G. M. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 1995 Apr 8;345(8954):882–885. doi: 10.1016/s0140-6736(95)90008-x. [DOI] [PubMed] [Google Scholar]
  72. den Heijer M., Koster T., Blom H. J., Bos G. M., Briet E., Reitsma P. H., Vandenbroucke J. P., Rosendaal F. R. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996 Mar 21;334(12):759–762. doi: 10.1056/NEJM199603213341203. [DOI] [PubMed] [Google Scholar]

Articles from Transactions of the American Ophthalmological Society are provided here courtesy of American Ophthalmological Society

RESOURCES